HK Stock Market Move | INNOVENT BIO(01801) rose over 5% in the first quarter, with product revenue increasing by over 50% year-on-year. is advancing three high-value potential molecules.

INNOVENT BIO (01801) rose by over 5%, reaching a 5.18% increase as of the time of this report, trading at 89.25 Hong Kong dollars with a turnover of 325 million Hong Kong dollars. On the news front, on April 30th, INNOVENT BIO announced that in the first quarter of 2026, the company's product revenue exceeded 3.8 billion yuan, a year-on-year increase of over 50%. This strong momentum confirms the successful execution of the company's "dual-wheel drive" strategy. The company's leading position in the field of oncology is becoming increasingly significant, with five tyrosine kinase inhibitors (TKIs) being rapidly included in the National Reimbursement Drug List (NRDL) after the addition. At the same time, the comprehensive product line has become a strong emerging driver of revenue growth for the company, mainly due to the outstanding performance of core products such as Tyvyt (camidexoride injection),Sintilimab (Tyrosine Kinase inhibitor), and Toripalimab (Temsirolimus N01 injection). The announcement stated that INNOVENT BIO continues to promote globalization and innovation, opening up continuous growth space for the company's value. The company is advancing three high-value potential molecules - IBI363 (PD-1/IL-2-biased dual-specific antibody), IBI343 (CLDN18.2ADC), and IBI324 (VEGF/ANG2 dual-specific antibody) - into or about to enter global multi-center Phase III clinical trials, while continuing to increase investment in early-stage innovation to drive global clinical development pipelines in the fields of next-generation oncology, cardiovascular and metabolic (CVM), autoimmune and ophthalmology.